364 related articles for article (PubMed ID: 32230938)
1. Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.
Kagabu M; Nagasawa T; Sato C; Fukagawa Y; Kawamura H; Tomabechi H; Takemoto S; Shoji T; Baba T
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230938
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Uterine Cervical Cancer.
Kagabu M; Nagasawa T; Fukagawa D; Tomabechi H; Sato S; Shoji T; Baba T
Healthcare (Basel); 2019 Sep; 7(3):. PubMed ID: 31533297
[TBL] [Abstract][Full Text] [Related]
3. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
Shim SH; Lee JY; Lee YY; Park JY; Lee YJ; Kim SI; Han GH; Yang EJ; Noh JJ; Yim GW; Son JH; Kim NK; Kim TH; Kong TW; Choi YJ; Cho A; Lim H; Jang EB; Cho HW; Suh DH
J Gynecol Oncol; 2024 Mar; 35(2):e66. PubMed ID: 38330382
[TBL] [Abstract][Full Text] [Related]
4. The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer.
Otter SJ; Chatterjee J; Stewart AJ; Michael A
Clin Oncol (R Coll Radiol); 2019 Dec; 31(12):834-843. PubMed ID: 31331818
[TBL] [Abstract][Full Text] [Related]
5. Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer.
Li Y; Shen F; Tan Q; Chen Y; Gu Y
Technol Cancer Res Treat; 2023; 22():15330338231208846. PubMed ID: 37908109
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Ventriglia J; Paciolla I; Pisano C; Cecere SC; Di Napoli M; Tambaro R; Califano D; Losito S; Scognamiglio G; Setola SV; Arenare L; Pignata S; Della Pepa C
Cancer Treat Rev; 2017 Sep; 59():109-116. PubMed ID: 28800469
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations.
Kurnit KC; Reid P; Moroney JW; Fleming GF
Gynecol Oncol; 2020 Sep; 158(3):531-537. PubMed ID: 32641238
[TBL] [Abstract][Full Text] [Related]
8. Management of brain metastases from lung cancer in the era of immunotherapy: a review of the literature.
Veccia A; Kinspergher S; Dipasquale M; Caffo O
Future Oncol; 2021 Feb; 17(5):597-609. PubMed ID: 33401981
[TBL] [Abstract][Full Text] [Related]
9. Boosting the abscopal effect with chemoradiotherapy/immunotherapy combination in metastatic cervical cancer: a case report.
Zhang W; Chen M; Xiang Q; Sun S; Cao H; Xie C; Qiu H
Immunotherapy; 2023 Oct; 15(15):1239-1247. PubMed ID: 37491886
[TBL] [Abstract][Full Text] [Related]
10. Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma.
Lin W; Lin A; Li Z; Zhou C; Chen C; Chen B; Lyu Q; Zhang J; Luo P
Biomed Pharmacother; 2020 Nov; 131():110633. PubMed ID: 32892029
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer.
Feng CH; Mell LK; Sharabi AB; McHale M; Mayadev JS
Semin Radiat Oncol; 2020 Oct; 30(4):273-280. PubMed ID: 32828383
[TBL] [Abstract][Full Text] [Related]
12. Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings.
Castañon E; Sanchez-Arraez A; Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A
Eur J Cancer; 2020 Sep; 136():159-168. PubMed ID: 32698098
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
14. Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation.
Dyer BA; Feng CH; Eskander R; Sharabi AB; Mell LK; McHale M; Mayadev JS
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):396-412. PubMed ID: 32942005
[TBL] [Abstract][Full Text] [Related]
15. Evolving standards and future directions for systemic therapies in cervical cancer.
Ang DJM; Chan JJ
J Gynecol Oncol; 2024 Mar; 35(2):e65. PubMed ID: 38282261
[TBL] [Abstract][Full Text] [Related]
16. Advances in the application of immune checkpoint inhibitors in gynecological tumors.
Zou Y; Xu Y; Chen X; Zheng L
Int Immunopharmacol; 2023 Apr; 117():109774. PubMed ID: 37012881
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Cervical Cancer.
Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.
Longoria TC; Tewari KS
Drugs; 2015 Nov; 75(16):1853-65. PubMed ID: 26474780
[TBL] [Abstract][Full Text] [Related]
19. Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review.
Borella F; Preti M; Bertero L; Collemi G; Castellano I; Cassoni P; Cosma S; Carosso AR; Bevilacqua F; Gallio N; Benedetto C; Micheletti L
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375467
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy and targeted therapy for cervical cancer: an update.
Menderes G; Black J; Schwab CL; Santin AD
Expert Rev Anticancer Ther; 2016; 16(1):83-98. PubMed ID: 26568261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
